Long-Term Data Back Anti-PD-1 in Advanced Non-Squamous NSCLC

(MedPage Today) -- Long-term data from an early first-line trial of pembrolizumab (Keytruda) plus chemotherapy showed that more than half of patients with advanced non-squamous non-small cell lung cancer (NSCLC) remained alive at 3 years.
In cohort...